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An Introduction to Extended-Release 

Injectable Naltrexone for the Treatment 

of People With Opioid Dependence
 
The U.S. Food and Drug Administration (FDA) 
approved extended-release injectable naltrexone 
(Vivitrol) in October 2010 to treat people with opioid 
dependence. This medication provides patients with 
opioid dependence the opportunity to take effective 
medication monthly, as opposed to the daily dosing 
required by other opioid dependence medications 
(i.e., methadone, buprenorphine, oral naltrexone). 
Extended-release injectable naltrexone was approved 
by FDA in 2006 to treat people with alcohol 
dependence. 
Treatment of opioid dependence remains a national 
priority. According to the 2010 National Survey 
on Drug Use and Health, approximately 359,000 
individuals reported either dependence on or abuse of 
heroin, and 1.92 million individuals reported either 
dependence on or abuse of prescribed painkillers.1 
The Treatment Episode Data Set (TEDS) reports that 
between 1998 and 2008 the percentage of individuals 
ages 12 and older who entered substance abuse 
treatment because of pain reliever abuse increased 
more than fourfold—from 2.2 percent to 9.8 percent.2 
This Advisory provides behavioral health 
professionals—including substance abuse treatment 
specialists—and primary care medical providers 
(who treat people with opioid dependence) with an 
introduction to extended-release injectable naltrexone. 
It includes succinct information about extended-
release injectable naltrexone, how it compares with 
other medication-assisted treatment (MAT) options, 
and clinical strategies that may be used to select, 
initiate, and administer treatment. 
What Role Can Extended-
Release Injectable Naltrexone 
Play in the Treatment of Opioid 
Dependence? 
Extended-release injectable naltrexone is another 
pharmacological tool that is approved for treatment 
of people with opioid dependence. Over the years, 
medications have been successful in treating many 
patients with opioid dependence. Methadone has been 
used to treat patients for decades and has been proven 
effective.3 However, methadone must be dispensed to 
the patient at a Substance Abuse and Mental Health 
Services Administration (SAMHSA)-certified opioid 
treatment program (OTP) facility—with daily doses 
provided at the clinic—until the patient is deemed 
stable enough to receive take-home doses. Barriers to 
accessing this treatment include limited geographical 
locations of OTPs, transportation difficulties, and 
policies that preclude the use of methadone. 
Buprenorphine, approved in 2002 by FDA to treat 
opioid dependence, is available at OTPs but is 
most often prescribed by physicians in office-based 
settings. Thus, in theory, it can be more accessible 
than methadone. However, to prescribe buprenorphine,
physicians need limited special training and so all 
physicians may not currently be able to prescribe 
it. Physicians also need to be granted a waiver by 
the U.S. Drug Enforcement Agency (DEA) from 
regulations that otherwise prohibit them from treating
people with opioid dependence in office settings and, 
at maximum, can only treat up to 100 patients at a 
time. Currently, mid-level practitioners (e.g., nurse 
practitioners, physician assistants) are not eligible for 
DEA waivers to prescribe buprenorphine. 
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Naltrexone can be prescribed by any healthcare provider
who is licensed to prescribe medications. Special training 
is not required; the medication can be administered in
OTP clinics. Practitioners in community health centers or 
private office settings can also prescribe it for purchase 
at the pharmacy. These factors may improve access to 
treatment for opioid dependence. 
Naltrexone requires that patients be abstinent from opioids 
for a period prior to induction. Such abstinence can be 
difficult for patients to achieve. Retention in treatment 
has sometimes been problematic when patients are asked 
to adhere to daily doses of oral naltrexone.4 A monthly 
injection of naltrexone, instead of daily dosing, may 
improve patients’ adherence to their medication 
regimens.5,6 
Extended-release injectable naltrexone has a higher 
pharmacy cost than buprenorphine and methadone, 
but some data suggest that its use may reduce inpatient 
admissions, emergency room visits, and other health 
system costs.7 Nonetheless, the higher pharmacy cost of 
extended-release injectable naltrexone may limit access 
for patients who lack health insurance or other financial 
resources. 
How Does Extended-Release 
Injectable Naltrexone Differ From 
Other Forms of MAT for Opioid 
Dependence? 
Both methadone and buprenorphine are controlled sub­
stances, whereas naltrexone is not. Methadone is an opioid 
agonist, buprenorphine is a partial opioid agonist, and nal­
trexone is an opioid antagonist. 
Different types of opioid receptors—or molecules to which
opioid compounds attach themselves and exert their ef­
fects—are present in the brain. Agonists are drugs that 
activate these receptors, binding to them and producing an 
effect. Opioids such as methadone, morphine, and heroin 
are full agonists and have the greatest abuse potential. 
Antagonists also bind to opioid receptors, but rather than 
producing an effect, they block the effects of opioid com­
pounds. Partial agonists bind to the receptors and activate 
them, but not to the same degree as full agonists.8 
Naltrexone has no abuse potential, whereas methadone 
and buprenorphine do. Further information about the 
pharmacology of methadone can be found in Treatment 
Improvement Protocol (TIP) 43: Medication-Assisted 
Treatment for Opioid Addiction in Opioid Treatment 
Programs.9 Additional information about buprenorphine 
is available in TIP 40: Clinical Guidelines for the Use of 
Buprenorphine in the Treatment of Opioid Addiction.8 
Some physicians are reluctant to prescribe agonists to 
treat opioid dependence because of their treatment phi­
losophies, difficulties in tapering patients off these medi­
cations, or the potential for illicit diversion of agonist 
medications.5 Physicians with these concerns may be more
comfortable prescribing an antagonist, such as naltrexone, 
rather than agonists. 
Exhibit 1 summarizes key differences between extended-
release injectable naltrexone, buprenorphine, and metha­
done. 
How Does Extended-Release 
Injectable Naltrexone Work? 
Naltrexone is an opioid antagonist, a medication that binds 
to and effectively blocks opioid receptors.8,10 It prevents 
receptors from being activated by agonist compounds, 
such as heroin or prescribed opioids, and is reported to 
reduce opioid cravings and to prevent relapse.11,12 Patients 
need to be informed that this medication will prevent 
them from feeling the euphoric effect or pain relief they 
previously felt when they took an opioid.10,13,14 
Are There Safety Concerns About 
Extended-Release Injectable 
Naltrexone? 
Risk of accidental opioid overdose 
and death 
Accidental overdoses and overdose-related deaths have 
occurred among patients who have taken opioids while 
being treated for opioid dependence with naltrexone­
containing products—including both the extended-release 
injectable formulation and the daily oral formulation.15,16 
Overdoses and overdose-related deaths are also a risk with 
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agonist therapies. No comprehensive mortality data are 
yet available about extended-release injectable naltrexone, 
but cases of fatal opioid overdose have been reported in 
patients who: 
●		Used opioids at or near the end of the 1-month dosing 
interval. 
●		Used opioids after missing a dose of extended-release 
injectable naltrexone. 
●		Attempted to overcome the opioid blockade.10 
Patients who have been treated with extended-release 
injectable naltrexone may have reduced tolerance to opioids 
and may be unaware of their potential sensitivity to the 
same, or lower, doses of opioids that they used to take. If 
patients who are treated with extended-release injectable 
naltrexone relapse after a period of abstinence, it is possible 
that the dosage of opioid that was previously used may 
have life-threatening consequences, including respiratory 
arrest and circulatory collapse.10 
Physicians have an obligation to educate patients who are 
treated with naltrexone-containing products about mortality 
risks that exist during and after leaving treatment for opioid
dependence.13, 17 Behavioral health providers may play a
role in reminding patients of these risks. It is recommended 
that providers and patients develop a relapse prevention 
plan that includes strategies to decrease the risks if relapse 
occurs. If patients continue to use opioids during treatment, 
transition to agonist medications may be considered to 
reduce mortality risk, although these medications also have 
mortality risks.13,17 
Risk of precipitating withdrawal 
Naltrexone displaces heroin or prescribed opioids 
from receptors to which they have bound, which can 
precipitate withdrawal symptoms.8,  20 Therefore, complete 
detoxification from opioids before initiating or resuming 
extended-release injectable naltrexone is necessary to 
prevent withdrawal. At least 7–10 days without opioid 
use is recommended before beginning extended-release 
injectable naltrexone.10,16 
Exhibit 1: Key Differences Between Medications Used  

To Treat Patients With Opioid Dependence
 
Prescribing
Considerations 
Extended-Release
Injectable Naltrexone 
Buprenorphine Methadone 
Frequency of
Administration 
Monthly Daily Daily 
Route of
Administration 
Intramuscular injection in the
gluteal muscle by healthcare
professional. 
Oral tablet or film is dissolved
under the tongue. Can be
taken at a physician’s office or
at home. 
Oral (liquid) consumption
usually witnessed at an OTP,
until the patient receives take-
home doses. 
Restrictions on
Prescribing or
Dispensing 
Any individual who is licensed
to prescribe medicine
(e.g., physician, physician
assistant, nurse practitioner)
may prescribe and order
administration by qualified
staff. 
Only licensed physicians
who are DEA registered and
either work at an OTP or have
obtained a waiver to prescribe
buprenorphine may do so. 
Only licensed physicians who
are DEA registered and who
work at an OTP can order
methadone for dispensing at
the OTP. 
Abuse and Diversion
Potential 
No Yes Yes 
Additional
Requirements 
None; any pharmacy can fill
the prescription. 
Physicians must complete
limited special training to
qualify for the DEA prescribing
waiver. Any pharmacy can fill
the prescription. 
For opioid dependence
treatment purposes,
methadone can only be
purchased by and dispensed
at certified OTPs or hospitals. 
Sources: Adapted from 16,18,19 
3 
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Adverse events 
The most frequently reported adverse events include hepatic
enzyme abnormalities, injection site pain, common cold 
symptoms, insomnia, and toothache. Nausea, vomiting, 
muscle cramps, dizziness, sedation, decreased appetite, 
and an allergic form of pneumonia have also occurred 
in people treated with extended-release injectable 
naltrexone.10,21 
Injection site reactions 
Injection site reactions—including pain, hardness, 
swelling, blisters, redness, bruising, abscesses, and tissue 
death—have been reported to FDA. Some reactions are 
serious enough that surgery is needed.16 
To reduce the risk of serious injection site reactions: 
●		Extended-release injectable naltrexone should be 

administered as an intramuscular injection into 

the gluteal muscle using the specially designed 

administration needle provided. It should never 

be administered intravenously, subcutaneously, 

or inadvertently into fatty tissues.
 
●		Extended-release injectable naltrexone should be 

administered into alternating buttocks (sides of the 

patient) each month.
 
●		Healthcare providers should consider alternate 
treatments for patients whose body size, shape, or 
posture makes it impossible to administer extended-
release injectable naltrexone in the recommended 
location. Note that the needle provided is not a 
standard needle (see last bullet). It is not possible 
to substitute a standard needle of a longer length. 
●		Patients who develop injection site reactions that 

do not improve should be referred to a surgeon.
 
●		The packaging of extended-release injectable 
naltrexone was changed in 2010. Both 1.5- and 2-inch 
needles are included for injecting the medication, to 
accommodate patients’ different body sizes. Use the 
2-inch needle for most patients and reserve the shorter 
needle for lean patients.10,16 
Liver adverse effects 
The FDA requires warnings on formulations of naltrexone 
about possible liver adverse effects. The current product 
labeling for extended-release injectable naltrexone 
includes a warning about hepatotoxicity when the 
medication is given in more than the recommended 
dose. Use of the medication is contraindicated in patients 
with acute hepatitis or liver failure. The medication 
manufacturer states that the margin of separation between 
the apparently safe dose and the dose causing hepatic 
injury appears to be only fivefold or less.10 Extended-
release injectable naltrexone should be discontinued if 
signs or symptoms of hepatitis develop (e.g., fatigue, 
loss of appetite, nausea, vomiting, abdominal pain, gray-
colored bowel movement, joint pain, jaundice).10 Further 
research and postmarket surveillance are underway to 
determine any long-term effects of this formulation on 
the liver. 
Which Patients May Benefit Most 
From Treatment With Extended-
Release Injectable Naltrexone? 
It is difficult to predict which medication will work for 
a particular patient with opioid dependence. Factors 
affecting a patient’s treatment success with a medication 
may change over time or with subsequent treatment 
attempts. Extended-release injectable naltrexone benefits 
people with opioid dependence who are at risk for opioid 
use immediately after detoxification.6 People facing 
periods of greatly increased stress or other relapse risks 
(e.g., visiting places of previous drug use, loss of spouse, 
loss of job) may find they benefit from the reassurance of 
the blockade provided by the medication.11,13 People who 
have a short or less severe history of dependence may also 
want to consider injectable naltrexone.6 Still others may 
have to demonstrate to professional boards, supervisors, 
drug court judges, or other authorities that their risk of 
using a nonprescribed opioid is low and the extended-
release formulation may provide an option that has 
reduced risk compared with other options. No definitive 
research is available that states which patients would 
most benefit from extended-release injectable naltrexone, 
but the following people may be good candidates for 
treatment. 
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People who have not had treatment 
success with methadone or 
buprenorphine 
Depending on the reasons for treatment failure, people 
with opioid dependence who have not been successful 
with treatment with methadone or buprenorphine may 
benefit from extended-release injectable naltrexone.22 
People who have a high level of 
motivation for abstinence 
People who are highly motivated to achieve and maintain 
abstinence from opioids may be good candidates for
extended-release injectable naltrexone.12,23 This includes 
people who are required to demonstrate abstinence with 
drug screens, such as individuals in impaired healthcare 
provider programs, parolees, probationers, and airline 
pilots.24 Preliminary results from an ongoing study of U.S. 
healthcare professionals with opioid dependence suggest 
that this treatment can be successful for up to 1 year.25 
People successful on agonists who 
wish to change their medication or 
patients not interested in agonist 
therapy to treat their opioid
dependence 
Some patients may be successful on agonist treatment and 
want continued pharmacologic help to prevent relapse 
but would prefer another type of treatment,22 while other 
patients may never be interested in agonist therapy. These 
types of patients could include individuals who: 
●		Feel they are discriminated against, or are embarrassed 
or ashamed, because they are on methadone maintenance
or who previously experienced these emotions while 
undergoing methadone therapy.26 
●		Would like to reduce the time devoted to daily or 

multiple OTP visits per week, as is often required 

for methadone treatment.13
 
●		Prefer to receive office-based treatment in a primary 
medical care setting, rather than treatment in specialty 
clinics or treatment centers.24,26 
Adolescents or young adults with 
opioid dependence 
Methadone or buprenorphine are not always available 
to treat young people with opioid dependence because 
of OTP facility policies or governmental regulations. 
However, the safety and efficacy of extended-release 
injectable naltrexone have not been established for patients 
who are younger than age 18, and use for this population is 
not approved by FDA. Only limited experience in treating 
this population with extended-release injectable naltrexone 
is reported in the literature.26 
Can Extended-Release Injectable 
Naltrexone Be Used With 
Behavioral Therapies? 
For most patients with opioid dependence, medications 
alone are insufficient. Treatment in individual or group 
counseling sessions and participation in mutual-help 
programs are also needed. Patients have better treatment 
outcomes when naltrexone-based treatment is combined 
with behavioral therapies.4,6,27 The efficacy of extended-
release naltrexone has been established when given in 
conjunction with behavioral support; it has not been 
studied as a sole component of treatment. 
Healthcare providers should be ready to offer brief 
intervention if patients relapse during treatment of opioid 
dependence. Motivational interviewing and relapse 
prevention strategies may also enhance the effectiveness 
of pharmacological treatments.8 
How Can Pain Be Treated During 
or After Extended-Release 
Injectable Naltrexone Treatment? 
Pain management in people receiving all forms of 
MAT, including extended-release injectable naltrexone, 
can be challenging. Some people can be safely and 
effectively treated with nonpharmacologic remedies, 
such as physical therapy, massage, or acupuncture, as 
long as the injection site is protected. Pain relief may 
also be obtained from nonopioid topical medications,
nonsteroidal anti-inflammatory agents, regional blocks, 
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and nonopioid painkillers such as gabapentin and atypical
antidepressants.13 
Use of opioid-containing analgesics may aggravate
preexisting addiction disorders and cause relapse. People
with opioid dependence who require opioid therapy for 
chronic pain should be managed by pain management 
specialists. In light of its antagonist property, extended-
release injectable naltrexone may not be appropriate for 
these patients.22 
Reversing blockade of opioid 
receptors 
There are few clinical trial data available about reversing 
the opioid receptor blockade. When surgeries or
procedures are planned for patients who use extended-
release injectable naltrexone, it may be safest to delay the 
procedure until naltrexone blood levels are low enough 
to restore opioid receptor availability. The manufacturer 
of extended-release injectable naltrexone also suggests 
considering use of regional analgesia or nonopioid 
analgesics.10 
In emergencies, it is possible for healthcare providers to 
reverse extended-release injectable naltrexone’s opioid 
receptor blockade. However, higher than usual dosages 
of a rapidly acting opioid medication may be needed 
to achieve pain relief if a patient still has a tolerance 
to opioids. These higher dosages increase the risk of 
respiratory depression. Patients administered such high 
doses should be closely monitored by professionals trained 
in the use of anesthetic drugs, management of respiratory 
depression, and the performance of cardiopulmonary 
resuscitation.10,16 
Patients who are treated with extended-release injectable 
naltrexone should be encouraged to wear medical alert 
jewelry or carry a disclosure card to help emergency 
personnel provide pain management safely when 
these patients are unconscious or cannot otherwise 
communicate. 
Resources 
Several publications are available free of charge from 
SAMHSA. The resources listed below can be ordered 
from SAMHSA’s Publications Ordering Web page at 
http://www.store.samhsa.gov. Or call 1-877-SAMHSA-7 
(1-877-726-4727) (English and Español). Publications 
can also be downloaded from the Knowledge Application 
Program Web site at http://www.kap.samhsa.gov. 
Resources for professionals 
Substance Abuse Treatment Advisory: Naltrexone for 
Extended-Release Injectable Suspension for Treatment 
of Alcohol Dependence. (2007). Volume 6, Issue 1. HHS 
Publication No. (SMA) 07-4267. 
Substance Abuse Treatment Advisory: Emerging Issues in 
the Use of Methadone. (2009). Volume 8, Issue 1. HHS 
Publication No. (SMA) 09-4368. 
Treatment Improvement Protocol (TIP) 40: Clinical 
Guidelines for the Use of Buprenorphine in the Treatment 
of Opioid Addiction. (2004). HHS Publication No. (SMA) 
07-3939. 
TIP 43: Medication-Assisted Treatment for Opioid 
Addiction in Opioid Treatment Programs. (2005). HHS 
Publication No. (SMA) 08-4214. 
TIP 45: Detoxification and Substance Abuse Treatment. 
(2006). HHS Publication No. (SMA) 08-4131. 
Resources for clients 
The Facts About Naltrexone for Treatment of Opioid 
Addiction. (2009). HHS Publication No. (SMA) 09-4444. 
Medication-Assisted Treatment for Opioid Addiction: 
Facts for Families and Friends. (2009). HHS Publication 
No. (SMA) 09-4443. 
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Other Web resources for medical and 
health professionals 
National Institute on Drug Abuse, NIDAMED 
http://www.drugabuse.gov/nidamed 
U.S. Food and Drug Administration
http://www.fda.gov 
For specific information on extended-release injectable 
naltrexone: http://www.accessdata.fda.gov/drugsatfda_docs/
label/2010/021897s005s010lbl.pdf 
For specific information on adverse injection site reactions:
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrug­
SafetyInformationforPatientsandProviders/ucm103334.htm 
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